RxDoctor Payments Data

Monica Santiago Nunez, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1942293642

Payments from drug & device makers

$2,030in general payments, 2019–2025

Across 94 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$513
  • Novo Nordisk$276
  • AbbVie$182
  • Johnson & Johnson$173
  • Boehringer Ingelheim$151
  • Abbott$141
  • plus $594 from 5 others

What the payments were for

  • Food & beverage$1,91895%
  • Education$1115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,030 in reported general payments places this provider in the 25th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,074
Medicare patients
30
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide470$470,451
JardianceEmpagliflozin392$271,560
Synjardy XrEmpagliflozin/Metformin Hcl387$265,836
TrulicityDulaglutide148$160,376
FarxigaDapagliflozin Propanediol231$148,070
MounjaroTirzepatide126$134,668
JanuviaSitagliptin Phosphate119$92,761
SynthroidLevothyroxine Sodium1,218$86,009
Janumet XrSitagliptin Phos/Metformin Hcl135$82,733
RybelsusSemaglutide66$66,097
Xigduo XrDapaglifloz Propaned/Metformin97$65,161
TradjentaLinagliptin72$42,794
ProliaDenosumab23$40,488
GlyxambiEmpagliflozin/Linagliptin46$34,307
JanumetSitagliptin Phos/Metformin Hcl54$32,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Trijardy Xr$151$648,688936 claims
Novo NordiskOzempic, Rybelsus, Novolog$276$537,497548 claims
MerckJanuvia, Janumet Xr, Janumet$109$207,820308 claims
AstraZenecaFarxiga$513$148,070231 claims
AbbVieSynthroid$182$86,0091,218 claims
Sanofi-aventis U.S. LLCLantus$100$31,773223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →